This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
midgardfinance.com
midgardfinance.com
did:plc:6elkozr74dmgtebnjmwcre7e
Lilly SURPASS-CVOT study result 🫀
Mounjaro not inferior to Trulicity
Primary endpoint:
Risk of cardiovascular death, heart attack, or stroke 8% lower for Mounjaro than Trulicity, but p = 0.086 📊
https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated
#Tirzepatide #Dulaglutide #Mounjaro #Trulicity #$LLY #NCT04255433
2025-07-31T11:58:23.809Z